entertainment -WSS

entertainment

author：explore 2025-08-26 23:48:18 - browse：3

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Boston hospital trains restaurant workers on naloxone for overdoses

WSS

Galapagos to make CAR

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Affirmative action in medical school literally saved lives

WuXi Biologics beefs up its lobbying operation

Free medical tuition alone isn't enough to close gaps in primary care

At least 13 dead in Texas as scorching temps continue

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Apple is now the first public company to be valued at $3 trillion

At least 13 dead in Texas as scorching temps continue

Anesthesiologist group: stop taking Ozempic before surgery

Continuity nursing helped my family in our darkest PICU moments

Medicare proposal to cover medical devices draws a mixed reaction

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

At least 13 dead in Texas as scorching temps continue

Obesity drug from Roche shows promise in early study

In age of alternative facts, a scholarly course on calling out crap

At least 13 dead in Texas as scorching temps continue

focus

Novo Nordisk testing Wegovy against alcohol

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Free medical tuition alone isn't enough to close gaps in primary care

In Memoriam: Notable people who died in 2023

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

leisure time

explore

leisure time

hotspot